Exploring a New Generation of Patient-Centric Cancer Clinical Trials by AACR will be held on January 21, 2025, Virtually.
The forum will explore the new generation of patient-centric cancer clinical trials, focusing on how advancements in cancer research will reshape the clinical trial process. As more people are expected to survive and live beyond cancer, largely due to clinical trials, the conference will highlight the ongoing transformation in trial design. The emphasis will be on creating more efficient, inclusive, and patient-focused trials that prioritize patient needs and preferences. This shift will be critical in ensuring broader access to innovative treatments and improving overall patient outcomes.
The upcoming session will feature a group of esteemed experts in the field of cancer research. Jan Tomlinson from the University of California, San Francisco, will share insights from a patient advocate’s perspective on the clinical trial experience. Patricia M. LoRusso, DO, PhD (HC), FAACR, from Yale Cancer Center, will discuss innovative clinical trial designs aimed at improving efficiency and inclusivity. David A. Tuveson, MD, PhD, FAACR, from CSHL Cancer Center, will highlight the Cancer Therapeutics Initiative, which focuses on translating basic research into clinical applications. Laura van ‘t Veer, PhD, from the University of California, San Francisco, will present on the second-generation design of the I-SPY 2 trial, driving advancements in precision medicine. These experts will cover a broad range of topics, all geared toward advancing cancer clinical trials and patient care.
